ReviewRSC advances2026
BODIPY-based photosensitizers for cancer phototherapy: photophysical modulation, ROS-mediated cell death and phototheranostic applications.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Boron-dipyrromethene (BODIPY)-based systems represent a versatile class of photosensitizers for cancer phototherapy due to their tunable photophysical properties, structural stability and multifunctional adaptability. This review presents an integrated perspective on BODIPY photochemistry at the interface of tumor microenvironment (TME) engineering, regulated cell death (RCD), and cancer immunotherapy. Review begins with a summary of the fundamental photophysical principles of light absorption, excited state dynamics, and reactive oxygen species (ROS) generation, which are the basis for rational photosensitizer design, advanced molecular engineering strategies such as the extension of π-conjugation, modulation of intersystem crossing, heavy-atom-free design and subcellular targeting are further highlighted for optimizing photodynamic performance. Particular attention is paid to TME-responsive systems that allow spatiotemporal activation under conditions such as hypoxia, acidity, and redox imbalance, which not only improve therapeutic selectivity but also actively reprogram the tumor microenvironment, further ROS mediated regulated cell death pathways such as apoptosis, ferroptosis and pyroptosis and their integration into immunogenic cell death and systemic immune activation studied. Review also discusses the combination of photodynamic therapy and immunotherapy, including multifunctional platforms that combine ROS generation and immune modulation to improve antitumor efficacy. Moreover, the recent advances of imaging-guided theranostic systems are summarized to show the capabilities of BODIPY-based platforms in real-time monitoring and precision therapy. Finally, current challenges related to oxygen dependence, formulation, biosafety, biodegradability and clinical translation are discussed, together with future directions for the development of adaptive and clinically relevant systems. Overall, this review provides a unifying framework linking BODIPY molecular design with biological and therapeutic outcomes, offering insights into the development of next-generation BODIPY-based phototheranostic platforms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.